新型GABAAR拮抗剂靶向高级别胶质瘤前沿的网络基因枢纽
研究通过加权基因共表达网络分析(WGCNA)识别弥漫性中线胶质瘤(DMG)和胶质母细胞瘤中的离子通道基因枢纽,并利用单细胞RNA测序、空间转录组学和免疫组化在患者肿瘤中验证其表达。结果显示GABAAR基因GABRA1和GABRG2位于肿瘤前沿,而GBO表达GABRA5;α5-GABAAR拮抗剂S44819和部分拮抗剂GABA(A)-compound 1b可抑制GBO侵袭和增殖,与标准治疗联用抗侵袭作用增强。
要点
- WGCNA识别出HGG中保守的「神经元调控」模块,其基因富集于肿瘤前沿。
- GABAAR亚基GABRA1和GABRG2在肿瘤前沿与GABA能突触标记共定位。
- α5-GABAAR拮抗剂S44819和GABA(A)-compound 1b抑制GBO侵袭和增殖,与放化疗联用增强效果。
核心结论
- HGG前沿存在关键离子通道枢纽,GABAAR靶向药物可破坏肿瘤进展。
研究设计与样本
- 对DMG和胶质母细胞瘤RNAseq数据进行WGCNA识别离子通道基因枢纽。
- 利用scRNA-seq、空间转录组学和免疫组化在患者肿瘤中验证枢纽表达。
- 在患者来源胶质母细胞瘤外植体类器官(GBO)中测试离子通道抑制剂单用或联合放疗和替莫唑胺的疗效。
主要发现
- 网络分析揭示HGG中保守的「神经元调控」模块,含最多离子通道,其基因集中于肿瘤前沿。
- 模块枢纽包括GABAAR基因GABRA1(α1)和GABRG2(γ2),免疫组化显示其与GABA能突触标记在前沿共定位。
- GBO未保留该突触结构,但表达胶质母细胞瘤枢纽GABRA5(α5),为突触外GABAAR组分。
- S44819(α5-GABAAR拮抗剂)强烈抑制GBO侵袭;GABA(A)-compound 1b(GABAAR部分拮抗剂) robustly抑制GBO增殖和侵袭。
- 与标准治疗(SOC)方案联用,两种化合物的抗侵袭特性在GBO中增强。
临床怎么用
- GABAAR拮抗剂可能作为HGG抗侵袭治疗策略,尤其与标准治疗联用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ion channel activity underlying biological processes that drive high-grade gliomas (HGG) is largely unknown. We aimed to determine the networking of ion channel genes and validate their expression within HGG patient tumors, to identify ion channel-targeting drugs that would inhibit tumor-promoting processes. METHODS: We used weighted gene co-expression network analysis (WGCNA) of RNAseq data to identify ion channel gene hubs in diffuse midline glioma (DMG) and glioblastoma. Using scRNA-seq, spatial transcriptomics, and immunohistochemistry, we characterized the expression of identified hubs within patient tumors, validating their role by testing the efficacy of ion channel inhibitors alone or in combination with radiation and temozolomide on the growth and invasion of patient-derived glioblastoma explant organoids (GBOs). RESULTS: Network analysis revealed a preserved HGG "neuronal regulation" module, containing the greatest number of ion channels, with its corresponding genes concentrated at the tumor's leading edge. Hubs within this module included γ-Aminobutyric-acid type A receptor (GABAAR) genes GABRA1 (α1) and GABRG2 (γ2), which immunohistochemically colocalized with GABAergic synaptic markers at the leading edge. GBOs failed to retain this synaptic architecture but expressed a glioblastoma hub GABRA5 (α5), a component of extrasynaptic GABAARs. S44819, an α5-GABAAR antagonist strongly inhibited GBO invasion, with GABA(A)-compound 1b, a partial antagonist of GABAARs, robustly inhibiting GBO proliferation and invasion. Moreover, combined with standard-of-care (SOC) regimens, the anti-invasive properties of both compounds were enhanced in GBOs. CONCLUSIONS: Our co-expression network analysis identified key ion channels at the leading edge in HGGs, which can be targeted by GABAAR-acting drugs to disrupt tumor progression.
引用
- Shard C, Jones AC, Fouladzadeh A, et al. Novel GABAAR antagonists target networked gene hubs at the leading edge in high-grade gliomas. Neuro Oncol. 2025. PMID: 40497637. doi:10.1093/neuonc/noaf143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。